← Back to Search

PACHA Program for Breast Cancer (PACHA Trial)

N/A
Recruiting
Research Sponsored by CHU de Quebec-Universite Laval
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Were diagnosed with a first non-metastatic, hormone-sensitive breast cancer
At least one women has initiated adjuvant endocrine therapy (AET) in the last 6 months in the pharmacy
Must not have
For women living in a residential facility where AET is not self-managed
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline to 5 years post-randomisation
Awards & highlights

Summary

This trial will assess how a community pharmacy-based program impacts adherence and experience of women having AET after hormone-sensitive breast cancer.

Who is the study for?
This trial is for women over 18 in Quebec, Canada who have started adjuvant endocrine therapy (AET) for the first time within the last 6 months after being diagnosed with non-metastatic, hormone-sensitive breast cancer. Participants must be fluent in French, have internet access, and agree to stay with their current pharmacy throughout the study.
What is being tested?
The PACHA program is being tested to see if it helps women stick to their AET after breast cancer. It's a community pharmacy-based support system that includes web training for pharmacists and resources like videos and booklets for patients. The study will compare pharmacies using PACHA against those providing usual care.
What are the potential side effects?
Since this trial focuses on adherence support rather than a medical intervention, there are no direct side effects from drugs or treatments involved. However, participants may experience varying levels of satisfaction or psychological impact from the additional support.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My first breast cancer was non-spreading and responsive to hormones.
Select...
I started hormone therapy for cancer in the last 6 months.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I live in a facility where I do not manage my own endocrine therapy.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline to 5 years post-randomisation
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline to 5 years post-randomisation for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Cluster size
Mean change from baseline to the end of 6-month follow-up in adjuvant endocrine therapy knowledge
Mean change from baseline to the end of 6-month follow-up in anticipated regret
+13 more
Secondary study objectives
Mean change from baseline to the end of 6-month follow-up in quality of life
Program Acceptability and Feasibility
Proportion of days covered by an Adjuvant Endocrine Therapy (AET)
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: PACHA program groupExperimental Treatment1 Intervention
Pharmacists and women in the PACHA program group will receive the PACHA program component's.
Group II: Usual care groupActive Control1 Intervention
Pharmacists and women in the Usual care group will provide/receive usual care.

Find a Location

Who is running the clinical trial?

Fondation Cancer du Sein du QuébecUNKNOWN
Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,373 Previous Clinical Trials
26,519,176 Total Patients Enrolled
10 Trials studying Breast Cancer
4,611 Patients Enrolled for Breast Cancer
Quebec Breast Cancer FoundationOTHER
6 Previous Clinical Trials
826 Total Patients Enrolled
5 Trials studying Breast Cancer
728 Patients Enrolled for Breast Cancer
~16 spots leftby Mar 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top